Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive Exforge data

Novartis reports positive Exforge data

29th July 2008

Novartis has announced the publication of new data showing Exforge helps almost twice as many patients control their high blood pressure compared to treatment solely with amlodipine.

Exforge is a single-pill combination of amlodipine with Diovan (valsartan).

Study data reveals patients on Exforge with baseline blood pressure of greater or equal to 180 mmHg showed reductions of up to 40 mmHg to help them reach target levels.

Furthermore, significant reductions in blood pressure were seen across a range of difficult-to-treat patient groups, including individuals with diabetes, the obese and elderly.

These results were printed in the most recent issue of the Journal of the American Society of Hypertension.

Trevor Mundel, head of global development functions at Novartis Pharma, said: “Exforge consistently demonstrates large blood pressure drops across all stages of high blood pressure and has been shown to get as many as nine out of 10 patients without diabetes to goal.”

He added that it is key to treat patients early and effectively to lower the risk of complications from high blood pressure that is uncontrolled.

Last month, Novartis announced that Exforge had received final approval from the US Food and Drug Administration.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.